Nuclear magnetic resonance

Nanalysis Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Monday, April 29, 2024
International, Depreciation, Airport, Depression, Interest, Artificial intelligence, NMR, Artificiality, Ground substance, International Financial Reporting Standards, Detection, Nuclear magnetic resonance, NRC, Security, Bank statement, Growth, Hertz, Q&A

Gross margin percentage on product sales was 41% for the twelve months ended December 31, 2023, down from 49% in the prior year.

Key Points: 
  • Gross margin percentage on product sales was 41% for the twelve months ended December 31, 2023, down from 49% in the prior year.
  • Because of these cost-cutting measures, as well as improved sales markets, gross margin percentage on product sales rose to 48% in the fourth quarter.
  • Services gross margin percentage was (23%) for the twelve months ended December 31, 2023.
  • EBITDA loss for the twelve months ended December 31, 2023, was $8,074K versus an EBITDA loss of $3,935K in the same period last year.

Bluefors Launches Helium Recovery Solution for Single Unit NMR Systems

Retrieved on: 
Monday, April 8, 2024
Nuclear magnetic resonance, NMR, Organization, Helium, Industrial gas

HELSINKI, Finland, April 8, 2024 /PRNewswire/ -- Bluefors today announced the Cryomech HeRL02-RM – a new Helium Reliquefier designed specifically for helium recovery from a single Nuclear Magnetic Resonance (NMR) unit.

Key Points: 
  • HELSINKI, Finland, April 8, 2024 /PRNewswire/ -- Bluefors today announced the Cryomech HeRL02-RM – a new Helium Reliquefier designed specifically for helium recovery from a single Nuclear Magnetic Resonance (NMR) unit.
  • Helium Reliquefiers help to conserve the use of valuable helium, safeguarding users against helium supply issues and protecting against helium price fluctuations.
  • "The HeRL02-RM is an ideal solution for small laboratories with one to three NMR systems, and organizations with dispersed magnets.
  • For facilities with greater helium boil off, Bluefors continues to offer full scale helium recovery solutions.

Nanalysis Corp. Receives Funding Supporting AI Software Development for Detection of Illicit Substances

Retrieved on: 
Thursday, April 4, 2024
Nuclear magnetic resonance, Prohibition, Culture, NSCI, Substance abuse, MRI, Artificiality, NRC, AB, NMR, Research, FRA, Plasma protein binding, LKA, AI, NPS, Laboratory, Nanalysis, OTCQX, National Research Council, Artificial intelligence, Medical imaging

This characterization requires an array of different analytical techniques and is carried out by skilled forensic scientists in thousands of laboratories worldwide.

Key Points: 
  • This characterization requires an array of different analytical techniques and is carried out by skilled forensic scientists in thousands of laboratories worldwide.
  • In many cases these laboratories face significant sample backlog due to volume and may have difficulties in identifying new designer drugs.
  • These tools will not only identify known illicit drugs but will also identify unknown drugs that are derivatives of known illicit substances also referred to as designer drugs or new psychoactive substances (NPS).
  • The company is developing this application in the context of its quantitative NMR platform technology, which has other applications as well, beyond illicit drug detection.

Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19

Retrieved on: 
Wednesday, February 21, 2024
OTCQB, RSV, Virology, Nuclear magnetic resonance, Viral, Vaccine, Lower respiratory tract infection, University, COVID-19, Virus, Patient, Clinical trial, Molar, Carbohydrate, Mutation, Research

BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced that the first patients have been treated with ProLectin-M in its dose optimization trial. ProLectin-M is intended to become a first line treatment for standard risk COVID-19 patients, but based on the broad-spectrum in vitro discovery could easily expand to upper respiratory tract infections. Following this dose optimization trial, Bioxytran intends to use the trial data to inform the design of the Phase 3 registrational trial in India, while also adhering to the FDA’s request for additional data.

Key Points: 
  • Following this dose optimization trial, Bioxytran intends to use the trial data to inform the design of the Phase 3 registrational trial in India, while also adhering to the FDA’s request for additional data.
  • The multi-center clinical trial in India will be a randomized double-blind placebo-controlled trial and is set to enroll 40 patients.
  • “After we complete the dose optimization trial, the next regulatory milestone is a registrational trial,” said Dr. Leslie Ajayi, Bioxytran’s medical director.
  • “We are on the cusp of completing a clinical trial of standard risk patient that contracted COVID-19.

NUCLEAR MAGNETIC RESONANCE (NMR) RESEARCH: CERTIFIED ORIGINS PRESENTS AT THE DOP/IPG SCIENTIFIC SYMPOSIUM IN ROME

Retrieved on: 
Tuesday, February 28, 2023
Olive, Marketing, EVOO, NMR, Safety, Yu-Gi-Oh!, DNA, University, PDO, Chosen-ciphertext attack, Farmer, Consorzio ICoN, Research, Database, Università Telematica Universitas Mercatorum, Certification, Multimedia, Science, PGI, University of Salento, Olive oil, Private label, Nuclear magnetic resonance, Medical imaging, Oracle

Certified Origins specializes in Private Label food programs where efficiency, safety, and quality are vital.

Key Points: 
  • Certified Origins specializes in Private Label food programs where efficiency, safety, and quality are vital.
  • "We take traceability very seriously here in Certified Origins.
  • The research results were presented at the first-ever scientific symposium fully dedicated to PDO and PGI-certified foods, organized by Fondazione Qualivita in Rome, Italy.
  • "High-quality EVOOs suitable for PDO and PGI certification may also undergo additional checking according to Nuclear Magnetic Resonance, based on reference databases.

In-line UV-vis Spectroscopy Market Size, Share & Trends Analysis Report 2022: Pharmaceutical/Chemical - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 20, 2023
Pharmaceutical, Hardware, Technology, Food, Beverage, Retail, Science, Chemicals, Plastics, Other Technology, Food Tech, Manufacturing, Other Science, Health, Internal, Pharmaceutical industry, Nuclear magnetic resonance, Laboratory, Protein, Therapy, Certified reference materials, Chemical industry, Workflow, Environmental monitoring, NBE, USP, National Institute of Standards and Technology, Indium gallium arsenide, European Pharmacopoeia, Certification, Spectrophotometry, Research, United States Pharmacopeia, Calibration, LED, Dicarboxylic acid, USD, Quality control, Pharmacy, Non-Euclidean geometry, Agriculture, IR, COVID-19, NMR, Silicon, Ultraviolet–visible spectroscopy, Sewage treatment, Speciality chemicals, Medical device, Video game

The "In-line UV-vis Spectroscopy Market Size, Share & Trends Analysis Report by Application (Color Measurement, Chemical Concentration), by End-user (Pharmaceutical Industry, Chemical Industry), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "In-line UV-vis Spectroscopy Market Size, Share & Trends Analysis Report by Application (Color Measurement, Chemical Concentration), by End-user (Pharmaceutical Industry, Chemical Industry), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • UV/Visible spectrophotometers are widely used by laboratories, including that associated with academia and governments, as well as other industries.
  • Thus, accurate calibration of the wavelength axis is important for applications that rely on spectroscopic techniques for compound testing, to receive regulatory approval.
  • These factors have driven the use of other spectroscopy methods, thereby limiting the revenue growth in this industry.

Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial

Retrieved on: 
Wednesday, December 28, 2022
MOA, Investigational New Drug, OTCQB, COVID-19, Central Drugs Standard Control Organisation, Galectin, NMR, Patient, Preprint, FDA, Nuclear magnetic resonance, CDSCO, Crystal, IND, Lactose, Pharmaceutical industry

Crystal research reported that the Company announced positive topline safety and efficacy results from its randomized, placebo-controlled Phase 2 clinical trial in 34 patients with mild-to-moderate COVID-19.

Key Points: 
  • Crystal research reported that the Company announced positive topline safety and efficacy results from its randomized, placebo-controlled Phase 2 clinical trial in 34 patients with mild-to-moderate COVID-19.
  • The Company’s analysis also revealed an 88% response rate by day 3, which was statistically significant (p-value=.001).
  • The trial’s objective is to provide guidance for a 408 patient Phase III trial that will be finalized after analyzing the data from the optimization trial.
  • The update also covered the mechanism of action (MOA) detailed in the latest pre-print in greater depth.

Alpha Lithium Achieves Best Grades To-Date at Tolillar Salar, Argentina

Retrieved on: 
Monday, December 19, 2022
Lithium, Diamond, Fresh water, Accounting, NI, Mining, PG, Technische Universität Darmstadt, Surface nuclear magnetic resonance, Research, Society, SME, News, Carbonate, NEO, QP, Porosity, Alpha, Associate, Consultant, OTC, Registered, Nuclear magnetic resonance, Student, Lithium carbonate, HR, Metallurgy, German

WBALT15 was drilled over 700 meters west of WBALT7, which returned very similar lithium concentrations, but with an even higher transmissivity value of 240 m2/day.

Key Points: 
  • WBALT15 was drilled over 700 meters west of WBALT7, which returned very similar lithium concentrations, but with an even higher transmissivity value of 240 m2/day.
  • All operations in Argentina are being managed by Alpha Lithium Argentina SA (“Alpha SA”) utilizing local employees and consultants.
  • Mr. Rosko has extensive experience in salar environments and has been a QP on many lithium brine projects.
  • Mr. Rosko and M&A are independent of Alpha Lithium Corp. Mr. Rosko has reviewed and approved the scientific and technical content of this news release.

Transitus Energy and Proteum Energy Are to Collaborate on Producing Hydrogen in the UK and Europe From North Sea Natural Gas Resources

Retrieved on: 
Thursday, December 22, 2022
Other Energy, Software, Utilities, Oil, Gas, Hardware, Alternative Energy, Energy, Technology, Ireland, Partnership, PTE, BCP, Transport, CCS, Nuclear magnetic resonance, Natural gas, LOI, Power, Ethanol, Carbon, Hydrogen production, Renewable energy, Hydrogen, Transitus

Proteum Energy® (Proteum) and Transitus Energy (Transitus) have entered into a Letter of Intent (LOI) to explore joint development opportunities in the UK, Netherlands, Republic of Ireland and Norway to produce low-carbon hydrogen.

Key Points: 
  • Proteum Energy® (Proteum) and Transitus Energy (Transitus) have entered into a Letter of Intent (LOI) to explore joint development opportunities in the UK, Netherlands, Republic of Ireland and Norway to produce low-carbon hydrogen.
  • “Proteum Energy is excited to join with Transitus to accelerate the UK’s and Europe’s transition to a clean energy economy by reforming natural gas resources from North Sea production into reliable, economical, clean hydrogen.
  • “Working with Proteum Energy and their cutting edge SnMR hydrogen technology will enable Transitus to convert wet natural gas into clean, robust, and affordable hydrogen.
  • www.transitusenergy.com
    About Proteum Energy® – Headquartered in Phoenix Arizona, Proteum is a producer of low-cost clean hydrogen from residue, flare and underutilized natural gas resources and green renewable ethanol.

Nanalysis Reports Third Quarter 2022 Results

Retrieved on: 
Tuesday, November 29, 2022
Marketing, Growth, OTC, Agrochemical, AB, Food, Conference, Multimedia, HERE, TSX Venture Exchange, Security Service, Government, Security, CATSA, Q&A, Law enforcement, The Company, Canada, NMR, MRI, News, Mining, NSCI, Hertz, Research, Economic development, Depreciation, Business, Investment, FRA, Acquisition, Nuclear magnetic resonance, Canadian Air Transport Security Authority, Video game, Renewable energy, Medical device, Bank, Mobile phone, Medical imaging, Nanalysis

CALGARY, AB, Nov. 29, 2022 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company") (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable NMR machines and MRI technology for healthcare and industrial applications, releases its second quarter results endingSeptember 30, 2022.

Key Points: 
  • CALGARY, AB, Nov. 29, 2022 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company") (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable NMR machines and MRI technology for healthcare and industrial applications, releases its second quarter results endingSeptember 30, 2022.
  • Chief Executive Officer,Sean Krakiwskyand Interim Chief Financial Officer,Randall McRaewill host a conference call at5 P.M. Eastern Timetodayto discuss the results.
  • "I am pleased to report we have returned to our strong growth trajectory in the third quarter," saidSean Krakiwsky, Founder and CEO of Nanalysis.
  • We expect to see continued strength in our business in the fourth quarter, which has historically been a strong quarter for our business."